Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Management of Refractory or Relapsed Classic Hodgkin Lymphoma in Brazil

News

December 20, 2023
PRESS RELEASE: On December 12, 2023, a new review was published in Oncotarget, entitled, “Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability.” continue reading »

Immunotherapy Response in Primary vs Metastatic Pancreatic Cancer

Oncotarget

November 16, 2023
In this editorial, researchers delve into the immunotherapeutic challenges posed by the tumor microenvironment and liver metastasis in pancreatic cancer. continue reading »

Obesity Paradox and Lung Cancer, Metformin-based Therapeutic Opportunity?

News

November 15, 2023
PRESS RELEASE: On March 31, 2023, a new editorial was published in Oncotarget, entitled, “Obesity paradox and lung cancer, metformin-based therapeutic opportunity?” continue reading »

C/EBPβ Cooperates With MYB to Maintain the Oncogenic Program of AML Cells

News

November 13, 2023
PRESS RELEASE: on March 11, 2023, a new editorial perspective was published in Oncotarget, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.” continue reading »

Combined Inhibition of SHP2 and Mutated RTKs Prevent Acquired Resistance in Leukemia

News

November 8, 2023
PRESS RELEASE: On March 31, 2023, a new editorial was published in Oncotarget, entitled, “Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors.” continue reading »